Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)
Francesco Gelsomino(Azienda USL di Bologna), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Saverio Cinieri(Ospedale A. Perrino), Lorenzo Tofani(University of Florence), Fausto Barbieri(University of Modena and Reggio Emilia), Michele Tognetto(University of Aberdeen), Ida Colantonio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Daniela Baldari(Tumour Institute of Tuscany), Claudio Dazzi(Azienda Ospedaliero-Universitaria Careggi), Marcello Tiseo(University of Parma), Lucia Longo(Azienda Unita' Sanitaria Locale Di Modena), Luigi Cavanna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 2
Related Papers
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
|British Journal of Cancer|2019|1.3k
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|606